Older Melanoma Patients Have Better Response to Immune Checkpoint Blockade Therapy

Patient age correlates with response to immunotherapy in melanoma and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute.
12-Jun-2018 3:30 PM EDT Add to Favorites

The Wistar Institute and Harbour BioMed Join Forces to Advance Novel Antibody Therapies for Cancer and Infectious Diseases

Wistar and Harbour BioMed announce they have entered into a multi-year, multifaceted research collaboration to co-discover novel antibodies for the treatment of cancer and infectious diseases.
4-Jun-2018 12:05 PM EDT Add to Favorites

Wistar and Ben Franklin Technology Partners of Southeastern Pa. Forge Collaboration to Accelerate Technology Commercialization

Wistar and Ben Franklin Technology Partners of Southeastern Pennsylvania (Ben Franklin), a nonprofit conglomerate of partners providing direct/seed funding, mentorship and networks to strengthen enterprise development, have signed a Memorandum of...
27-Apr-2018 12:05 PM EDT Add to Favorites

Targeting Telomerase as a Therapeutic Strategy for Difficult-to-Treat Melanoma

Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in...
25-Apr-2018 12:05 PM EDT Add to Favorites

Wistar Team Receives Prestigious Award from National Clinical Research Forum for DNA-based Zika Research

Wistar and partners at the Perelman School of Medicine, University of Pennsylvania; Inovio Pharmaceuticals; and GeneOne Life Science were recognized among the Top 10 Clinical Research Achievement Awards by the Clinical Research Forum for their...
19-Apr-2018 10:05 AM EDT Add to Favorites

Top HIV Cure Research Team Refutes Major Recent Results on How to Identify HIV Persistence

An international team focused on HIV cure research spearheaded by The Wistar Institute in collaboration with the University of Pennsylvania and Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain, established that the CD32 molecule is not...
18-Apr-2018 10:20 AM EDT Add to Favorites

Soluble Antibodies Play Immune Suppressive Role in Tumor Progression

Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models.
12-Apr-2018 2:05 PM EDT Add to Favorites

Novel Combination Therapy Effective for NRAS Mutant and Therapy Resistant Melanoma

Wistar researchers have identified a novel therapeutic vulnerability in NRAS mutant melanoma and an effective strategy to address it, using a combination of two clinically relevant inhibitors, according to study results published online in EMBO...
11-Apr-2018 2:05 PM EDT Add to Favorites

see all news